News und Analysen
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-News: BB Biotech Q2 2025: outperforms Nasdaq Biotech Index; strong USD returns, currency drag in CHF
EQS-News: Abivax announces trading resumption of its ordinary shares on Euronext Paris
EQS-News: Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
EQS-News: Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
EQS-News: Abivax Announces Launch of Public Offering
EQS-News: Experienced biotechnology expert joins the Supervisory Board of BRAIN Biotech AG
Evolva Holding SA: Update about earn-out from Danstar
Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sales and Margin Outlook
EQS-News: Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
Humana Accelerates Efforts to Eliminate Prior Authorization Requirements to Ensure a Faster, More Seamless Process
Humana Inc., a leading health and well-being company, today announced accelerated efforts to approve care requests as quickly as possible and reduce the administrative burden for physicians
Sartorius Stedim Biotech SA: Information on Document Availability
Half-year results 2025 of Sartorius Stedim Biotech
Agilent to Announce Third-Quarter Fiscal Year 2025 Financial Results on Aug. 27
Following an announcement earlier this week, Agilent Technologies Inc. (NYSE: A) confirms it will release financial results for the third quarter of fiscal year 2025 after the stock market closes
GenSight Biologics Announces Publication on Predictors of Final Visual Outcome in Patients Treated with LUMEVOQ® Gene Therapy
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Inogen to Report Second Quarter 2025 Financial Results on August 7, 2025
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report second quarter 2025 financial
Humana Simplifies Access to Coverage and Care Information
Humana Inc. [NYSE: HUM] announced today its latest collaboration with healthcare software company Epic, becoming the first health insurer to integrate health plan information directly into the
Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product
Agilent Announces CFO Transition
Agilent Technologies Inc. (NYSE: A) today announced that effective July 31, Senior Vice President and Chief Financial Officer Bob McMahon will step down from his role as he relocates to the East
Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2025 financial results on Wednesday, August 6th, before the market opens. A conference call has been scheduled
EQS-News: Eckert & Ziegler: Outstanding Training Quality Once Again Awarded
Simulations Plus Invests in Clinical Development Technology Company Nurocor
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical
XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive topline results from the overall survival (OS) analysis from the
EQS-News: Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business